FDA Approves First Fast-Acting Insulin Biosimilar for Diabetes
The US Food and Drug Administration (FDA) recently approved the rapid-acting human insulin analog insulin-aspart-szjj, marketed as Merilog, as a biosimilar to insulin aspart (Novolog).
The US Food and Drug Administration (FDA) recently approved the rapid-acting human insulin analog insulin-aspart-szjj, marketed as Merilog, as a biosimilar to insulin aspart (Novolog).
